John Thornback

John Thornback

Chairman at Centre For Probe Development & Commercialization

Health Technology
Consumer Services
Electronic Technology

Profile

John Thornback is currently the Chairman at Centre For Probe Development & Commercialization.
He previously worked as the Chief Executive Officer at Enigma Diagnostics Ltd., Chief Executive Officer & General Manager at Resolution Pharmaceuticals, Inc., Chief Executive Officer at Dx assays Pte Ltd., Director-Research & Development at Medgenix Diagnostics SA, Managing Director at Hammersmith Imanet Ltd., Managing Director at A.A.
Hammersmith Insurance, Inc., and Managing Director at Apta Biosciences Ltd.
He also worked as a Lecturer at Loughborough University and Chelsea College.
He is a Professor at Specialist Diabetes Research & Treatment Centre LLC.
Dr. Thornback completed his undergraduate and doctorate degrees from Imperial College London.

John Thornback active positions

CompaniesPositionStart
Chairman -
All active positions of John Thornback

Former positions of John Thornback

CompaniesPositionEnd
Loughborough University Corporate Officer/Principal 1987-12-31
Chief Executive Officer -
Chief Executive Officer -
Corporate Officer/Principal -
Chelsea College Corporate Officer/Principal -
See the detail of John Thornback's experience

Training of John Thornback

Imperial College London Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of John Thornback's experience

Connections

68

1st degree connections

14

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies11

Health Technology

Health Technology

Hammersmith Imanet Ltd.

Electronic Technology

Resolution Pharmaceuticals, Inc.

Communications

A.A. Hammersmith Insurance, Inc.

Health Services

Health Technology

Health Technology

Health Technology

See company connections
  1. Stock Market
  2. Insiders
  3. John Thornback
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW